Mannel Appointed as an NRG Oncology Group Chairman

PHILADELPHIA, PA — NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has announced that Robert S. Mannel, MD will serve as one of its three group chairmen effective September 1, 2017. He joins Drs. Walter J. Curran Jr. and Norman Wolmark as the NRG Oncology group chairmen and principal investigators of the group’s federal awards. He follows Philip J. DiSaia, MD in the role upon Dr. Disaia’s retirement after 46 years of outstanding service collectively to NRG Oncology and the Gynecologic Oncology Group (GOG) and his numerous contributions to ovarian cancer and gynecologic cancer research.

“I consider it a great honor and privilege to be appointed as a group chair for NRG Oncology and look forward to the continued success of this great organization. NRG Oncology is uniquely positioned to advance our care of women with gynecologic cancers and, with the dedication of group members, will continue to define the standard of care for the management of these patients. In addition, by bringing together the legacy groups NSABP, RTOG, and GOG to form the NRG Oncology, we have created the most diverse and impactful team in the NCTN, and our future potential is unlimited,” stated Mannel.

Mannel is currently director of the Stephenson Cancer Center, the Rainbolt Family Chair in Cancer, and a professor of obstetrics and gynecology at the University of Oklahoma. Prior to being appointed as an NRG Oncology group chairman, he served as chair of the NRG Oncology Gynecologic Committee, a member of the NCI Gynecologic Cancers Steering Committee, and corresponding PI for the University of Oklahoma LAPS site for the NCTN. Mannel will now serve as the Chair of the NRG Oncology Foundation Board of Directors.

Mannel’s extensive experience and thorough familiarity with NRG Oncology and the legacy GOG will greatly contribute to the future of the organization and its continued advancements in practice-changing cancer research. Mannel and recently-elected GOG Foundation Inc. president Larry J. Copeland, MD have already initiated a strategic planning process aimed to impact NRG Oncology’s upcoming Semiannual Meeting in Phoenix, Arizona in January 2018.

www.nrgoncology.org

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the NSABP Foundation, the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.